ST6GAL1 Antibody

說明書

中文名稱：

ST6GAL1兔多克隆抗體
貨號：

CSB-PA022759GA01HU
規格：

￥3,900
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P15907
基因名：

ST6GAL1
別名：

ST6GAL1; SIAT1; Beta-galactoside alpha-2,6-sialyltransferase 1; Alpha 2,6-ST 1; B-cell antigen CD75; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1; ST6Gal I; ST6GalI; Sialyltransferase 1
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Human ST6GAL1
免疫原種屬：

Homo sapiens (Human)
抗體亞型：

IgG
純化方式：

Antigen Affinity purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
產品提供形式：

Liquid
應用范圍：

ELISA,WB
Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Transfers sialic acid from CMP-sialic acid to galactose-containing acceptor substrates.
基因功能參考文獻：
1. Although ST6GalI overexpression increased HER2 sialylation, corresponding to decreased HER2 phosphorylation, high alpha2,6sialylation enhanced Akt and ERK phosphorylation levels compared to those in the vector cell line; ST6GalI knockdown had the opposite effects. Collectively, these results implicated a functional role of ST6GalI in promoting tumor cell progression and trastuzumab resistance. PMID: 30226606
2. cells grown in hypoxia for several weeks displayed enriched ST6Gal-I expression, consistent with a pro-survival function. Taken together, these findings unravel a glycosylation-dependent mechanism that facilitates tumor cell adaptation to a hypoxic milieu. PMID: 29475939
3. by restraining TNFR1 at the cell surface via sialylation, ST6Gal-I acts as a functional switch to divert signaling toward survival. These collective findings point to a novel glycosylation-dependent mechanism that regulates the cellular response to TNF and may promote cancer cell survival within TNF-rich tumor microenvironments. PMID: 29233887
4. ST6GAL1 might be a potential target for atherosclerosis prevention and treatment. PMID: 29654763
5. We discovered three significant associations at rs6679677 on 1p13.2 (P=6.15x10-5, OR=5.07), rs16861329 on 3q27.3 (P=2.02x10-4, OR=0.87) and rs849135 on 7p15.1 (P=6.59x10-9, OR=1.78), which suggested PTPN22, ST6GAL1 and JAZF1 as novel susceptibility genes for psoriasis in Chinese population. PMID: 28603863
6. Suggest a crucial role for ST6Gal1 in elevating the invasiveness of pancreatic ductal adenocarcinoma cells in a fructose-responsive manner. PMID: 28032597
7. these results indicate that ST6Gal-I plays a critical role in cell proliferation and invasion via the PI3K/Akt/GSK-3beta/beta-catenin signaling pathway during cancer progression PMID: 27588482
8. these results indicate that ST6Gal-I might play a positive role in mediating the survival of human hepatocarcinoma cells PMID: 27340870
9. The results demonstrate that epigenetic modulation of ST6Gal1 expression plays a key role in the glioma phenotype in vitro and that that therapeutic approaches targeting elements of the epigenetic machinery for the treatment of human glioblastoma are warranted. PMID: 27510958
10. The data confirm that circulatory ST6Gal-1 is a negative systemic regulator of granulopoiesis PMID: 28550122
11. Results provide evidence that ST6GAL1 contributes to drug resistance in cervical neoplasm. PMID: 27986075
12. High ST6GAL1 expression is associated with ovarian and pancreatic Cancers. PMID: 27216178
13. ST3Gal I and ST6Gal I have different sialic acid donor specificity. PMID: 28395125
14. Taken together, these results indicate a dynamic change in the expression of ST6GAL1 during the CRC progression and provide a list of sialylated proteins potentially relevant to the different functions of ST6GAL1 in CRC. PMID: 28377225
15. The results presented in this study provide an important advance by highlighting a new function for ST6Gal-I in promoting the viability of tumor cells exposed to the type of serum-depleted conditions often found in hypovascularized tumor microenvironments. PMID: 28154177
16. High ST6GAL1 expression is associated with aging. PMID: 26840264
17. Collectively, our data indicate that ST6GAL1 plays an important role in the regulation of pluripotency and differentiation in hPSCs. PMID: 26304831
18. These results suggest a role for ST6Gal-I to promote the growth and invasion of osteosarcoma cells. PMID: 26054692
19. Data indicate that O-glycan-specific alpha2,6 sialyltransferase regulate cancer growth and metastasis by regulating galectins Gal-1- and Gal-3-binding moieties on O-glycans. PMID: 26224120
20. Expression levels of sialyltransferases ST3GAL1 and ST3GAL4 were upregulated in the HRMECs after high-glucose stimulation. PMID: 26258617
21. Sialylation by beta-galactoside alpha-2,6-sialyltransferase regulates cell adhesion and invasion in human anaplastic large cell lymphoma. PMID: 25573487
22. CDX2 transcriptionally regulates ST6GalNAc-I gene expression, specifically in the preneoplastic intestinal metaplasia lesion. PMID: 25867765
23. Study characterizes ST6GAL1 expression loss caused by aberrant ST6GAL1 promoter methylation potentially indicating a tumor suppressive role in bladder carcinogenesis. PMID: 25465919
24. ST6GAL1 promotes TGF-beta-dependent epithelial-mesenchymal transition PMID: 25344606
25. The lymphocyte levels of NEU1 and ST6GAL1 mRNA expression are significantly increased in erythremia. PMID: 25566667
26. The study detected only one allele of each polymorphism in the ST6GAL1P1 promoter. PMID: 24606438
27. ST6GAL1 is responsible for the development of multidrug resistance in human leukemia cells probably through medicating the activity of PI3K/Akt signaling. PMID: 24454800
28. A large glycan from a symmetry mate localizes to the active site of ST6Gal-I in an orientation compatible with catalysis. The glycan binding mode can be generalized to any glycoprotein that is a substrate of ST6Gal-I. PMID: 23999306
29. the high expression of ST3Gal I and ST6Gal I, in skin tumors, is associated with tumors with greater potential for invasion and metastasis, as in the case of squamous cell carcinoma, and this may be related to their behavior. PMID: 23549466
30. ST6Gal-I protein expression is upregulated in epithelial tumors. PMID: 23358684
31. the suppressive role of Necl-2 in the HRG-induced ErbB2/ErbB3 signaling is regulated by miR-199a at least through the reduction of the ST6GAL1-catalyzed sialylation of Necl-2 PMID: 23504322
32. These results indicated that gastric cancer tissues expressed high levels of alpha 2,3-linked sialic acid residues, ST3Gal IV, and ST6Gal I. PMID: 21140242
33. Our results suggest that soluble ST6Gal may participate in cancer progression and metastasis prior to being secreted from cancer cells PMID: 22449099
34. ST6Gal-I regulates macrophage apoptosis via alpha2-6 sialylation of the TNFR1 death receptor. PMID: 21930713
35. CDw75 expression in colorectal tumoural tissue was correlated with growth pattern (p = 0.044), Dukes stage (p = 0.002), TNM stage (p = 0.020) and distant metastasis (p = 0.005). PMID: 21778787
36. the occurrence of CD75s- and iso-CD75s-gangliosides in tumor tissues is largely independent of the transcriptional expression of ST6GAL1 and ST3GAL6 PMID: 21147760
37. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. PMID: 21550977
38. ST6Gal I is responsible for ST2H antigen biosynthesis in human colon cancer cells. PMID: 20656882
39. siRNA targeting to ST6Gal I can effectively downregulate the ST6Gal I expression in HeLa cell and further lead to the decline of cell adhesion and invasiveness to ECM. PMID: 17441333
40. ST6Gal I and ST3Gal V were positively correlated with the high risk of pediatric acute leukemia. PMID: 19709745
41. enhanced tumour ST6Gal I activity and an increased CDw75 expression may play a role in malignant transformation of colorectal cancer PMID: 20003255
42. ST6Gal I sialyltransferase has a role in regulating galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death PMID: 12499376
43. Expression of alpha 2,6-sialyltransferase ST6Gal I is enhanced in cervical squamous cell carcinoma. PMID: 12798701
44. Transcriptional activation of beta-galactoside alpha2,6-sialyltransferase in colon adenocarcinoma cells. PMID: 12878221
45. High levels of ST6GAL-I in the tumor tissue correlated with secondary local tumor recurrence (p = 0.005; p = 0.012). PMID: 12931020
46. specific kinase enzymes have important roles in the expression and catalytic activity of the alpha2,6 STN (ST6N) isozyme PMID: 12943659
47. Neoplastic transformation but not cirrhosis can alter the process of alpha2,6-sialylation of liver glycoproteins. PMID: 14514712
48. sialyltransferases expression and activity are increased in Grave's disease PMID: 16053379
49. the presence of alpha2,6-linked sialic acid added by ST6Gal.I on membrane glycoconjugates increases the binding to extracellular matrix components, resulting in a membrane stabilization of beta1 integrins, further strengthening the binding PMID: 16192407
50. ST6Gal I is upregulated in tumor and transitional tissues from colorectal cancer patients PMID: 16319516
顯示更多

收起更多
亞細胞定位：

Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Secreted. Note=Membrane-bound form in trans cisternae of Golgi. Secreted into the body fluid.
蛋白家族：

Glycosyltransferase 29 family
數據庫鏈接：

HGNC: 10860

OMIM: 109675

KEGG: hsa:6480

STRING: 9606.ENSP00000169298

UniGene: Hs.207459

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human